Disease activity and current treatments
| Non-arthritis clinical SLEDAI | dsDNA(0–9.9) | C3 | C4 | Current treatment | Current prednisone (mg) | NSAID use | |
| 1 | 0 | 17 | nl | nl | Abatacept, tacrolimus | 25 | N |
| 2 | 0 | nl | nl | nl | HCQ, BEL | 5 | N |
| 3 | 0 | nl | nl | nl | AZA | 15 | Y |
| 4 | Leucopaenia | 145 | 44 | 6 | 0 | N | |
| 5 | Leucopaenia | 58 | 129 | 32 | HCQ, BEL | 0 | N |
| 6 | Rash | nl | nl | nl | HCQ | 15 | N |
| 7 | 0 | nl | nl | <5 | HCQ, AZA | 3 | N |
| 8 | 0 | 5 (4.9) | ND | ND | HCQ | 0 | Y |
| 9 | 0 | nl | nl | nl | HCQ | 5 | Y |
| 10 | 0 | 11 | nl | nl | HCQ, MTX | 5 | N |
| 11 | Rash, nephritis | nl | 66 | 10 | HCQ, MMF | 20 | N |
| 12 | 0 | nl | nl | nl | HCQ, MMF | 0 | N |
| 13 | OU | nl | nl | nl | HCQ, MMF, BEL | 5 | N |
| 14 | 0 | nl | nl | nl | HCQ | 10 | N |
| 15 | 0 | nl | nl | nl | HCQ, LEF | 7 | N |
| 16 | OU | 50 | 45 | 8 | HCQ, MMF | 10 | N |
| 17 | Rash | 20 | 35 | 6 | HCQ, AZA | 5 | Y |
| 18 | 0 | 17 | nl | nl | HCQ | 0 | N |
| 19 | 0 | nl | nl | nl | HCQ, AZA | 0 | N |
| 20 | Rash | nl | nl | nl | HCQ | 0 | Y |
Non-arthritis clinical SLEDAI criteria that would be counted towards SLEDAI other than serologies. Anti-dsDNA for patient 8 was on outside lab with a different reported range with top normal of 4.9. ‘nl’ is a normal value.
AZA, azathioprine; BEL, belimumab; dsDNA, double-stranded DNA; HCQ, hydroxychloroquine; LEF, leflunomide; MMF, mycophenolate; MTX, methotrexate; N, no; ND, not done; NSAID, non-steroidal anti-inflammatory drugs; OU, oral or nasal ulcers; SLEDAI, SLE Disease Activity Index; Y, yes.